Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635791 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00635791 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 36 participants.
The verdict
NCT00635791, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may stop the growth of solid tumors by blocking blood flow to the tumor. Giving vorinostat together with sorafenib tosylate may kill more tumor cells.
Interventions
- DRUG Vorinostat
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635791
The ClinicalTrials.gov registry entry for NCT00635791 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT00635791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635791 about?
NCT00635791 is a clinical study titled "Phase I Study of Vorinostat and Sorafenib in Advanced Cancer". This phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may ...
What is the current status of trial NCT00635791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00635791?
The interventions under investigation include: Vorinostat (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00635791?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.